Key result
Prehospital STEMI thrombolysis improves outcomes at ~AUD 16,750 per QALY gained vs. no treatment.
Why the study?
Is paramedic-administered prehospital thrombolysis cost-effective compared to an alternate treatment pathway without prehospital thrombolysis in patients with prehospital STEMI?
Is paramedic-administered prehospital thrombolysis cost-effective compared to an alternate treatment pathway without prehospital thrombolysis in patients with prehospital STEMI?
Paramedic-administered prehospital thrombolysis for STEMI in Queensland, Australia is cost-effective, costing AUD 16,750.22 (USD 11,725.15) per QALY gained over a lifetime horizon.
Answers are grounded in this paper and cite their sources.
Supports cost-effectiveness modeling for prehospital thrombolysis; hypothesis-generating and requires prospective trials before adoption.
Guidelines recommend prehospital thrombolysis for ST-segment elevation myocardial infarction (STEMI) if trained clinicians can interpret 12-lead electrocardiogram (ECG) on site. The Queensland Ambulance Service (QAS) has a well-established prehospital reperfusion program under which all paramedics are trained in prehospital STEMI diagnosis on 12-lead ECG and administering thrombolysis in the field to eligible patients. Whilst the clinical benefits of this treatment are proven, its cost-effectiveness remains to be established. We developed a decision-analytic microsimulation model to evaluate the cost-effectiveness of paramedic-administered thrombolysis for prehospital STEMI in the state of Queensland, Australia. The comparator was a hypothetical counterfactual group of patients who were clinically eligible for prehospital thrombolysis but received an alternate treatment pathway. The analysis was conducted from a health provider (Queensland Government) perspective. A lifetime time horizon was used. Input values of the acute phase were derived from our prehospital and linked hospital database of all STEMI patients receiving prehospital thrombolysis from QAS paramedics between January 2022 and December 2024. Input values of the long-term phase were obtained from published literature. Cost was expressed in Australian dollars (AUD) and United States dollars (USD) in 2026 value, and effectiveness in quality-adjusted life years (QALYs). Prehospital thrombolysis improved outcomes at a cost of AUD 16,750.22 per QALY gained (95% uncertainty range AUD 15,477.48 - 18,422.84) or USD 11,725.15 (USD 10,834.24 - 12,895.99). In the sensitivity analysis, the cost-effectiveness of prehospital thrombolysis was robust to changes in input values. Paramedic-administered thrombolysis in the field for prehospital STEMI, compared with no such treatment, represents value for money.
No takes yet. Share an insight, caveat, or question.
Doan et al. (2026) studied ST-segment elevation myocardial infarction (STEMI). Paramedic-administered prehospital thrombolysis vs. Hypothetical counterfactual group receiving an alternate treatment pathway (no prehospital thrombolysis) was evaluated on Incremental cost per quality-adjusted life year (QALY) gained (AUD 16,750.22 per QALY gained (USD 11,725.15 per QALY gained), 95% CI AUD 15,477.48-18,422.84 (USD 10,834.24-12,895.99)). Paramedic-administered prehospital thrombolysis for STEMI improved outcomes at a cost of AUD 16,750.22 per QALY gained compared with no such treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: